fundament outlook challeng
approach would consid
compel yield maintain hold stock given
concern compani fundament outlook next two year
project declin core pharma segment oper profit
indic pressur fundament concern earn
perform segment would inflect soon given broader pressur
brand drug price
summari ep beat tax continu pressur cordi spoil top-lin
beat beat top-lin vs strong perform specialti
growth among compani core custom partial off-set lost revenu
stem sale compani chines distribut busi close feb
well lap loss prime contract may miss
oper incom expect vs cordis-rel pressur larg
discretionari contribut off-set better expect perform
rx distribut busi despit op incom miss beat ep vs
due much lower anticip tax-rat
ep guidanc street expect headwind optum contract
re-pric linger gener pressur albeit sell-sid stabil loss
pharmerica result neg ebitda growth outlin
compani ep guidanc slightli consensu
expect management expect medic segment grow op incom
mid-to-high-singl digit rang headwind pharma distribut segment
includ optum contract re-pric linger gener pressur modest margin
compress despit moder sell-sid deflat loss pharmerica busi
expect result high-singl low-doubl digit declin segment op
incom growth
keep hold fundament outlook concern despit compel valuat
certainli could consid attract valuat perspect
yield maintain hold stock given concern compani
fundament outlook next two year present challeng cordi
busi potenti margin pressur contract re-pric assum re-sign
risk rx manufactur decid either forgo anoth round price increas
lower rx list price latter like caus signific st disrupt
distributor busi model along earn volatil
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
statement earn
page
pleas see import disclosur inform page report
 dollar million except per share data -fiscal year end growth good sell incom expens tax net net incom dilut share dilut growth ebitda growth oper growth good incom expens tax net incom
page
pleas see import disclosur inform page report
 dollar million except per share data -fiscal year end cash receiv expens current intang long-term portion long-term accru current long-term liab
statement flow
page
pleas see import disclosur inform page report
 dollar million except per share data -fiscal year end loss dispos defer incom bad fair valu capit invest consider short-term non-controlling oblig termin proce issuanc common compens tax compens tax chang ocf
inc healthcar servic compani provid pharmaceut medic product oper
medic segment segment distribut brand gener pharmaceut specialti pharmaceut over-
the-count healthcar consum product unit state oper nuclear pharmaci cyclotron facil provid
pharmaci manag servic hospit well medic therapi manag patient outcom servic hospit
healthcar provid payer provid servic healthcar compani support develop market distribut
specialti pharmaceut product repackag gener pharmaceut over-the-count healthcar product medic segment
distribut broad rang medic surgic laboratori product provid servic hospit ambulatori surgeri center clinic
laboratori healthcar provid unit state canada china well manufactur sourc develop
cardin brand medic surgic product sold unit state canada europ region intern
provid post-acut care manag transit servic softwar hospit healthcar provid payer
pt deriv appli pe/g ratio line stock histor delta vs pe/g lt growth assumpt risk
overhang med suppli cordi
maintain pt deriv use coverag univers average pe/g ratio acknowledg ep artifici depress
aet-rel interest expens price-to-earnings valuat unduli penal stock time gap debt rais deal
brian tanquilut certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
bryan ross cfa certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
jason plagman certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within period
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate secur averag
secur price consist expect total return price appreci plu yield plu minu within period
under-perform rate secur averag secur price consist expect total return price appreci plu yield minu
less within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/
jefferi polici
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
page
pleas see import disclosur inform page report
